Targeting WEE1 and asciminib suppresses ABL-tyrosine kinase inhibitor-resistant chronic myeloid leukemia cells
Abstract Background Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the uncontrolled proliferation of white blood cells. Tyrosine kinase inhibitors (TKIs) are the standard treatment; however, resistance to BCR::ABL1 mutations remains challenging. WEE1, a checkpoint k...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer
2025-07-01
|
| Collection: | Discover Oncology |
| Sujets: | |
| Accès en ligne: | https://doi.org/10.1007/s12672-025-03036-7 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|